DP Youtube

Cookies

"I’m excited about non-muscle-invasive bladder cancer and immune checkpoint inhibition for lots of different reasons.” Thomas Powles (Barts Health NHS Trust, London, UK) discusses the CREST trial, including the rationale, previous findings, and phase 3 results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. View transcript.

"It’s time to create new and novel agents.” Gary Steinberg (Rush University Medical Center, Chicago, USA) discusses cretostimogene grenadenorepvec, covering its mechanism of action and the associated clinical trial results. View transcript.

Cookie-less

"I’m excited about non-muscle-invasive bladder cancer and immune checkpoint inhibition for lots of different reasons.” Thomas Powles (Barts Health NHS Trust, London, UK) discusses the CREST trial, including the rationale, previous findings, and phase 3 results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. View transcript.

"It’s time to create new and novel agents.” Gary Steinberg (Rush University Medical Center, Chicago, USA) discusses cretostimogene grenadenorepvec, covering its mechanism of action and the associated clinical trial results. View transcript.